Literature DB >> 4038058

Late relapse from cutaneous stage I malignant melanoma.

H M Shaw, C W Beattie, W H McCarthy, G W Milton.   

Abstract

In 1,283 patients with cutaneous stage I malignant melanoma who had ten or more years of follow-up, the incidence of late recurrence (first evidence of metastases occurring ten or more years after melanoma diagnosis) was 2.7%. None of the factors of prognostic importance (anatomic site, tumor thickness, ulcerative state of primary lesion, or initial surgical treatment) proved useful in predicting those patients with late recurrence. There was no sex or age difference in either incidence of late recurrence or prognosis subsequent to recurrence. Prognosis subsequent to late recurrence depended on the site of the recurrence. Survival after distant metastases became evident was extremely short. However, in the majority (53%) of patients, late recurrence was local and survival subsequent to treatment of these metastases was often protracted, emphasizing the importance of long-term follow-up in all patients with cutaneous melanoma.

Entities:  

Mesh:

Year:  1985        PMID: 4038058     DOI: 10.1001/archsurg.1985.01390340053010

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  13 in total

Review 1.  Follow-up in patients with low-risk cutaneous melanoma: is it worth it?

Authors:  Ulrike Leiter; Thomas Eigentler; Claus Garbe
Journal:  Melanoma Manag       Date:  2014-12-04

2.  [Simultaneous enucleation of a pulmonary melanoma metastasis and myocardial revascularization].

Authors:  H Keller; R Hacker; M Stolte
Journal:  Med Klin (Munich)       Date:  1997-11-15

3.  A high proliferative index of recurrent melanoma is associated with worse survival.

Authors:  Ting J Tu; Michelle W Ma; Stefano Monni; Amy E Rose; Herman Yee; Farbod Darvishian; David Polsky; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Madhu Mazumdar; Iman Osman
Journal:  Oncology       Date:  2011-06-24       Impact factor: 2.935

4.  Malignant melanoma of the skin: long-term follow-up and time to first recurrence.

Authors:  Annika M Hohnheiser; Olaf Gefeller; Jonas Göhl; Gerold Schuler; Werner Hohenberger; Susanne Merkel
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

5.  Delayed systemic recurrence of uveal melanoma.

Authors:  Nathalie A Kolandjian; Caimiao Wei; Sapna P Patel; Jessica L Richard; Tina Dett; Nicholas E Papadopoulos; Agop Y Bedikian
Journal:  Am J Clin Oncol       Date:  2013-10       Impact factor: 2.339

6.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

7.  Detection and characterization of carcinoma cells in the blood.

Authors:  E Racila; D Euhus; A J Weiss; C Rao; J McConnell; L W Terstappen; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

8.  Late recurrence in melanoma: clinical implications of lost dormancy.

Authors:  Mark B Faries; Shawn Steen; Xing Ye; Myung Sim; Donald L Morton
Journal:  J Am Coll Surg       Date:  2013-05-03       Impact factor: 6.113

9.  Late recurrence of malignant melanoma. Analysis of 168 patients.

Authors:  N J Crowley; H F Seigler
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

10.  Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.

Authors:  April K S Salama; Nicole de Rosa; Randall P Scheri; Scott K Pruitt; James E Herndon; Jennifer Marcello; Douglas S Tyler; Amy P Abernethy
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.